A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Registration Number
NCT06065748
Lead Sponsor
Hoffmann-La Roche
Brief Summary

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-n...

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1050
Inclusion Criteria
  • Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
  • Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing)
  • Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing
  • Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after >/=12 months or off-treatment within 12 months of completion. Prior use of neo/adjuvant CDK4/6i is allowed.
  • No prior systemic anti-cancer therapy for advanced disease
  • Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1
  • For pre/perimenopausal women and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment
Read More
Exclusion Criteria
  • Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer
  • Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents
  • Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
  • Active cardiac disease or history of cardiac dysfunction
  • Clinically significant history of liver disease
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Fulvestrant + Investigator's Choice of CDK4/6iFulvestrantParticipants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Fulvestrant + Investigator's Choice of CDK4/6iLHRH AgonistParticipants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Giredestrant + Investigator's Choice of CDK4/6iLHRH AgonistParticipants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Giredestrant + Investigator's Choice of CDK4/6iFoundationOne Liquid CDx Assay (F1LCDx)Participants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Giredestrant + Investigator's Choice of CDK4/6iRibociclibParticipants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Giredestrant + Investigator's Choice of CDK4/6iGiredestrantParticipants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Fulvestrant + Investigator's Choice of CDK4/6iFoundationOne Liquid CDx Assay (F1LCDx)Participants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Fulvestrant + Investigator's Choice of CDK4/6iPalbociclibParticipants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Giredestrant + Investigator's Choice of CDK4/6iAbemaciclibParticipants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Giredestrant + Investigator's Choice of CDK4/6iPalbociclibParticipants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Fulvestrant + Investigator's Choice of CDK4/6iAbemaciclibParticipants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Fulvestrant + Investigator's Choice of CDK4/6iRibociclibParticipants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival (PFS) in the ESR1 mutation (ESR1m) SubgroupFrom randomization to first occurrence of progressive disease (PD) or death (up to 5 years)

PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), or death from any cause during the study.

PFS in the Full Analysis Set (FAS) PopulationFrom randomization to first occurrence of PD or death (up to 5 years)
Secondary Outcome Measures
NameTimeMethod
Time to Confirmed Deterioration (TTCD) in Pain SeverityFrom randomization until end of follow-up (up to 5 years)

TTCD in pain severity is defined as the time from randomization to the first documentation of ≥2-point increase from baseline on the "worst pain" item score of the Brief Pain Inventory-Short Form (BPI-SF). It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

Duration of Response (DOR)From the first occurrence of a documented objective response to PD or death (up to 5 years)

DOR is defined as the time from the first occurrence of a documented objective response to PD, as determined by the investigator according to RECIST v1.1, or death from any cause (whichever occurs first). It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

Incidence and Severity of Adverse EventsFrom Baseline until 28 days after the final dose of study treatment (up to 5 years)

Incidence will be reported as the number of participants with at least one adverse event, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE v5.0).

Number of Participants with Clinical Laboratory Test Abnormalities for Hematology and Biochemistry Parameters Over the Course of the StudyFrom Baseline until 28 days after the final dose of study treatment (up to 5 years)
Confirmed Objective Response Rate (cORR)From randomization until treatment discontinuation (up to 5 years)

The cORR is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart, as determined by the investigator according to RECIST v1.1. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

Clinical Benefit Rate (CBR)From randomization until treatment discontinuation (up to 5 years)

The CBR is defined as the percentage of participants with stable disease for at least (≥)24 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

Time to ChemotherapyFrom randomization until the start of chemotherapy or death (up to 5 years)

Time to chemotherapy is defined as the time from randomization until the start date of the first chemotherapy or death from any cause (whichever occurs first). It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

TTCD in Pain Presence and InterferenceFrom randomization until end of follow-up (up to 5 years)

TTCD in pain presence and interference is defined as the time from randomization to the first documentation of ≥10-point increase in pain score, as determined using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) questionnaire. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

TTCD in Role FunctioningFrom randomization until end of follow-up (up to 5 years)

TTCD in role functioning (RF) is defined as the time from randomization to the first documentation of ≥10-point decrease in RF score, as determined using the EORTC QLQ-C30 questionnaire. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

Number of Participants with Vital Sign Abnormalities Over the Course of the StudyFrom Baseline until 28 days after the final dose of study treatment (up to 5 years)

Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure, and temperature.

PFS in the ESR1 no-mutation-detected (ESR1nmd) SubgroupFrom randomization to first occurrence of PD or death (up to 5 years)
Overall Survival (OS)From randomization until death from any cause (up to 5 years)

OS is defined as the time from randomization to death from any cause. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

TTCD in Physical FunctioningFrom randomization until end of follow-up (up to 5 years)

TTCD in physical functioning (PF) is defined as the time from randomization to the first documentation of ≥10-point decrease in PF score, as determined using the EORTC QLQ-C30 questionnaire. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

TTCD in Global Health Status/Quality of LifeFrom randomization until end of follow-up (up to 5 years)

TTCD in in Global Health Status/Quality of Life (GHS/QoL) is defined as the time from randomization to the first documentation of ≥10-point decrease in GHS/QoL score, as determined using the EORTC QLQ-C30 questionnaire. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups.

Trial Locations

Locations (278)

Sutter Health Medical Center

🇺🇸

Sacramento, California, United States

Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie

🇩🇪

Bamberg, Germany

Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine

🇬🇷

Athens, Greece

Southern Cancer Center

🇺🇸

Daphne, Alabama, United States

TOI Clinical Research

🇺🇸

Cerritos, California, United States

Marin Cancer Care Inc

🇺🇸

Greenbrae, California, United States

Kaiser Permanente - Harbor City

🇺🇸

Harbor City, California, United States

USC Norris Comprehensive Cancer Center

🇺🇸

Los Angeles, California, United States

USC Norris Cancer Center; Oncology/Hematology - Newport Beach Treatment Center

🇺🇸

Newport Beach, California, United States

Florida Cancer Specialists - Fort Myers (Gladiolus Dr)

🇺🇸

Fort Myers, Florida, United States

Cancer Specialists of North Florida

🇺🇸

Jacksonville, Florida, United States

SCRI Florida Cancer Specialists PAN

🇺🇸

Tallahassee, Florida, United States

Florida Cancer Specialists - Tampa

🇺🇸

Tampa, Florida, United States

Grady Health System

🇺🇸

Atlanta, Georgia, United States

Zhongshan Hospital Fudan University

🇨🇳

Shanghai, China

Shanxi Province Cancer Hospital

🇨🇳

Taiyuan City, China

Taizhou Hospital of Zhejiang Province

🇨🇳

Taizhou, China

Tianjin Cancer Hospital; Department of Breast Oncology

🇨🇳

Tianjin, China

The Tumor Hospital of Xinjiang Medical University

🇨🇳

Urumqi, China

Union Hospital Tongji Medical College Huazhong University of Science and Technology

🇨🇳

Wuhan City, China

Hubei Cancer Hospital

🇨🇳

Wuhan, China

The Second Affiliated Hospital of Xi'an Jiao Tong University

🇨🇳

Xi'an City, China

Xi'an International Medical Center Hospital

🇨🇳

Xian, China

Centre Leon Berard; Departement Oncologie Medicale

🇫🇷

Lyon, France

Centre Cancerologie Grand Montpellier

🇫🇷

Montpellier, France

Institut Jean Godinot; Oncologie Medicale

🇫🇷

Reims CEDEX, France

Centre Eugene Marquis; Service d'oncologie

🇫🇷

Rennes, France

Gynonco Düsseldorf, MVZ Medical Center GmbH

🇩🇪

Düsseldorf, Germany

Universitätsklinikum Erlangen; Frauenklinik

🇩🇪

Erlangen, Germany

Kliniken Essen-Mitte

🇩🇪

Essen, Germany

Praxis für Interdisziplinäre Onkologie und Hämatologie GbR

🇩🇪

Freiburg, Germany

Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg

🇩🇪

Heidelberg, Germany

Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe

🇩🇪

Homburg/Saar, Germany

St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe

🇩🇪

Koeln, Germany

Rotkreuzklinikum München; Frauenklinik

🇩🇪

Muenchen, Germany

Brustzentrum Rhein-Ruhr Servicegesellschaft mbH

🇩🇪

Mönchengladbach, Germany

Alexandras General Hospital of Athens; Oncology Department

🇬🇷

Athens, Greece

Euromedical General Clinic of Thessaloniki; Oncology Department

🇬🇷

Thessaloniki, Greece

Celan S.A.

🇬🇹

Ciudad de Guatemala, Guatemala

INTEGRA Cancer Institute

🇬🇹

Ciudad de Guatemala, Guatemala

Onco Go, S.A.

🇬🇹

Ciudad de Guatemala, Guatemala

Sanatorio MEDIK-Cayala

🇬🇹

Ciudad de Guatemala, Guatemala

Grupo Angeles

🇬🇹

Guatemala City, Guatemala

Oncomedica

🇬🇹

Guatemala, Guatemala

Centro Medico Integral de Cancerologia CEMIC

🇬🇹

Quetzaltenango, Guatemala

Pamela Youde Nethersole Eastern Hospital; Clinical Oncology

🇭🇰

Hong Kong, Hong Kong

Queen Mary Hospital; Dept of Medicine

🇭🇰

Hong Kong, Hong Kong

Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly

🇭🇺

Budapest, Hungary

Bács-Kiskun Vármegyei Oktatókórház; Onkoradiológiai Központ

🇭🇺

Kecskemét, Hungary

B-A-Z Vármegyei Központi Kórház és Egyetemi Oktatókórház; Klin. Onkológiai és Sugárterápiás Centrum

🇭🇺

Miskolc, Hungary

Nograd Varmegyei Szent Lazar Korhaz; Onkologiai es Sugarterapias Centrum

🇭🇺

Salgótarján, Hungary

Max Super Speciality Hospital

🇮🇳

New Delhi, Delhi, India

HealthCare Global Enterprises Limited; Medical Oncology

🇮🇳

Banglore, Karnataka, India

MVR Cancer Centre and Research Institute

🇮🇳

Kozhikode, Kerala, India

Grant Medical Foundation, Ruby Hall Clinic

🇮🇳

Pune, Maharashtra, India

Hadassah Ein Karem Hospital; Oncology Dept

🇮🇱

Jerusalem, Israel

Rabin Medical Center; Oncology Dept

🇮🇱

Petah Tikva, Israel

Sheba MC

🇮🇱

Ramat Gan, Israel

Sourasky Medical Center; Oncology Department

🇮🇱

Tel-Aviv, Israel

Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati

🇮🇹

Avellino, Campania, Italy

Azienda Ospedaliera Universitaria Federico II

🇮🇹

Napoli, Campania, Italy

Policlinico S.Orsola-Malpighi; Istituto Oncologia R. Addarii

🇮🇹

Bologna, Emilia-Romagna, Italy

I.R.S.T Srl IRCCS; Oncologia Medica

🇮🇹

Meldola, Emilia-Romagna, Italy

A.O. Universitaria Di Parma

🇮🇹

Parma, Emilia-Romagna, Italy

RENATI INNOVATION S.A.P.I. de C.V

🇲🇽

Guadalajara, Jalisco, Mexico

Clinica Peruana Americana

🇵🇪

Trujillo, Peru

Instytut "Centrum Zdrowia Matki Polki"; Klinika Onkologii

🇵🇱

?ód?, Poland

Centrum Onkologii im. Prof. Franciszka ?ukaszczyka; Ambulatorium Chemioterapii

🇵🇱

Bydgoszcz, Poland

Szpital Morski Im. Pck; Oncology & Radiotherapy Dept

🇵🇱

Gdynia, Poland

Narodowy Instytut Onkologii Odzia? w Gliwicach; Centrum Diagnostyki i Leczenia Chorób Piersi

🇵🇱

Gliwice, Poland

Hospital Araujo Jorge; Departamento de Ginecologia E Mama

🇧🇷

Goiania, GO, Brazil

Hospital Sao Domingos

🇧🇷

Sao Luis, MA, Brazil

Hospital do Cancer de Pernambuco - HCP

🇧🇷

Recife, PE, Brazil

Instituto Nacional del Cancer

🇨🇱

Santiago, Chile

Icegclinic

🇨🇱

Santiago, Chile

Beijing Cancer Hospital

🇨🇳

Beijing, China

the First Hospital of Jilin University; Cancer Center

🇨🇳

Changchun City, China

Hunan Cancer Hospital

🇨🇳

Changsha CITY, China

West China Hospital of Sichuan University

🇨🇳

Chengdu City, China

Sichuan Provincial People's Hospital

🇨🇳

Chengdu, China

The First Affiliated Hospital, Chongqing Medical University

🇨🇳

Chongqing, China

Fujian Medical University Union Hospital

🇨🇳

Fuzhou City, China

No. 900 Hospital (Fuzhou General Hospital)

🇨🇳

Fuzhou City, China

Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology

🇨🇳

Guangzhou City, China

The Second Affiliated Hospital of Zhejiang University College

🇨🇳

Hangzhou, China

Harbin Medical University Cancer Hospital

🇨🇳

Harbin, China

Jinan Central Hospital

🇨🇳

Jinan City, China

Shandong Cancer Hospital

🇨🇳

Jinan, China

The First People's Hospital of Yunnan Province

🇨🇳

Kunming City, China

The First Affiliated Hospital to Henan University of Science and Technology

🇨🇳

Luoyang City, China

Guangxi Cancer Hospital of Guangxi Medical University

🇨🇳

Nanning City, China

Fudan University Shanghai Cancer Center

🇨🇳

Shanghai City, China

Hospital Universitario Virgen de La Arrixaca; Servicio De Oncologia

🇪🇸

El Palmar, Murcia, Spain

Hospital Alvaro Cunqueiro; Servicio de Oncologia

🇪🇸

Vigo, Pontevedra, Spain

Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica

🇪🇸

Barcelona, Spain

Hospital Juan Ramon Jimenez;Servicio de Oncologia

🇪🇸

Huelva, Spain

Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia

🇪🇸

Jaen, Spain

Centro Oncologico MD Anderson Internacional; Servicio de Oncologia

🇪🇸

Madrid, Spain

HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia

🇪🇸

Madrid, Spain

Hospital Universitario Virgen Macarena; Servicio de Oncologia

🇪🇸

Sevilla, Spain

Hospital Universitario Virgen del Rocio; Servicio de Oncologia

🇪🇸

Sevilla, Spain

Instituto Valenciano Oncologia; Oncologia Medica

🇪🇸

Valencia, Spain

Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia

🇪🇸

Valencia, Spain

Hsin-Chu Branch of National Taiwan University Hospital

🇨🇳

Hsinchu City, Taiwan

China Medical University Hospital; Surgery

🇨🇳

Taichung, Taiwan

Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology

🇨🇳

Taipei City, Taiwan

VETERANS GENERAL HOSPITAL; Department of General Surgery

🇨🇳

Taipei, Taiwan

National Taiwan Uni Hospital; Dept of Oncology

🇨🇳

Taipei, Taiwan

Veterans General Hospital - Taichung

🇨🇳

Xitun Dist., Taiwan

Chulalongkorn Hospital; Medical Oncology

🇹🇭

Bangkok, Thailand

National Cancer Institute; Clinical Research center

🇹🇭

Bangkok, Thailand

Chulabhorn Hospital; Medical Oncology

🇹🇭

Lak Si, Thailand

Maharaj Nakorn Chiang Mai Hospital; Depart of Radiology; Divis of Therapeutic Radiology and Oncology

🇹🇭

Muang Chiang MAI Delivery Branch 3, Thailand

Songklanagarind Hospital; Department of Oncology

🇹🇭

Songkhla, Thailand

CEDOES - Diagnóstico e Pesquisa

🇧🇷

Vitoria, ES, Brazil

Clínica Puerto Montt

🇨🇱

Puerto Montt, Chile

Centro De Cancer Universidad Catolica

🇨🇱

Santiago, Chile

The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente

🇺🇸

Torrance, California, United States

Rocky Mountain Cancer Centers

🇺🇸

Denver, Colorado, United States

Georgetown University Medical Center

🇺🇸

Washington, District of Columbia, United States

MedStar Washington Hosp Center

🇺🇸

Washington, District of Columbia, United States

Winship Cancer Institute of Emory University

🇺🇸

Atlanta, Georgia, United States

Mission Cancer + Blood - IMMC

🇺🇸

Des Moines, Iowa, United States

New England Cancer Specialists

🇺🇸

Scarborough, Maine, United States

Maryland Oncology Hematology

🇺🇸

Annapolis, Maryland, United States

Frederick Health Hospital

🇺🇸

Frederick, Maryland, United States

Dana Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Astera Cancer Care East Brunswick

🇺🇸

East Brunswick, New Jersey, United States

Oncology Hematology Care

🇺🇸

Cincinnati, Ohio, United States

Asante Rogue Regional Medical Center

🇺🇸

Medford, Oregon, United States

Ann B. Barshinger Cancer Institute

🇺🇸

Lancaster, Pennsylvania, United States

Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit

🇺🇸

Philadelphia, Pennsylvania, United States

WellSpan Oncology Research

🇺🇸

York, Pennsylvania, United States

Lifespan Cancer Institute

🇺🇸

Providence, Rhode Island, United States

Avera Cancer Institute - Aberdeen

🇺🇸

Aberdeen, South Dakota, United States

Avera Cancer Institute

🇺🇸

Sioux Falls, South Dakota, United States

West Cancer Center

🇺🇸

Germantown, Tennessee, United States

SCRI Oncology Partners

🇺🇸

Nashville, Tennessee, United States

Texas Oncology Cancer Center

🇺🇸

Austin, Texas, United States

Texas Oncology - Baylor Charles A. Sammons Cancer Center

🇺🇸

Dallas, Texas, United States

Crio - Centro Regional Integrado de Oncologia

🇧🇷

Fortaleza, CE, Brazil

Northwest Medical Specialties

🇺🇸

Tacoma, Washington, United States

Fundación CENIT para la Investigación en Neurociencias

🇦🇷

Buenos Aires, Argentina

Inst. de Oncologia Angel H. Roffo ; Oncology Dept

🇦🇷

Buenos aires, Argentina

Centro Oncologico Korben; Oncology

🇦🇷

Ciudad Autonoma Buenos Aires, Argentina

Sanatorio Allende

🇦🇷

Cordoba, Argentina

Centro Oncologico Riojano Integral (CORI)

🇦🇷

La Rioja, Argentina

Hospital Alemán

🇦🇷

Recoleta, Argentina

Instituto de Oncología de Rosario

🇦🇷

Rosario, Argentina

Sanatorio Parque S.A.

🇦🇷

Rosario, Argentina

Hospital Provincial del Centenario

🇦🇷

Rosario, Argentina

Centro Oncológico de Excelencia

🇦🇷

San Juan, Argentina

Northern Beaches Hospital

🇦🇺

Frenchs Forest, New South Wales, Australia

Nepean Hospital; Nepean Cancer Care Centre

🇦🇺

Kingswood, New South Wales, Australia

Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research

🇦🇺

North Sydney, New South Wales, Australia

University of the Sunshine Coast

🇦🇺

Sippy Downs, Queensland, Australia

Mater Misericordiae Limited

🇦🇺

South Brisbane, Queensland, Australia

Cancer Research SA

🇦🇺

Adelaide, South Australia, Australia

Barwon Health

🇦🇺

Geelong, Victoria, Australia

Sunshine Hospital

🇦🇺

St Albans, Victoria, Australia

South West Healthcare

🇦🇺

Warrnambool, Victoria, Australia

Medical University Innsbruck; Frauenklinik Innsbruck, Dept Gyn

🇦🇹

Innsbruck, Austria

Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1

🇦🇹

Linz, Austria

Oö. Gesundheits- und Spitals-AG/LKH Steyr

🇦🇹

Steyr, Austria

Cliniques Universitaires St-Luc

🇧🇪

Bruxelles, Belgium

UZ Gent

🇧🇪

Gent, Belgium

UZ Leuven Gasthuisberg

🇧🇪

Leuven, Belgium

CHU Sart-Tilman

🇧🇪

Liège, Belgium

Clinique Ste-Elisabeth

🇧🇪

Namur, Belgium

Sint Augustinus Wilrijk

🇧🇪

Wilrijk, Belgium

Obras Sociais Irma Dulce - Osid

🇧🇷

Salvador, BA, Brazil

Instituto D'Or de Pesquisa e Ensino

🇧🇷

Rio de Janeiro, RJ, Brazil

Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

🇧🇷

Ijui, RS, Brazil

Santa Casa de Misericordia de Porto Alegre

🇧🇷

Porto Alegre, RS, Brazil

Hospital Moinhos de Vento

🇧🇷

Porto Alegre, RS, Brazil

Hospital Nossa Senhora da Conceicao

🇧🇷

Porto Alegre, RS, Brazil

Hospital Sao Lucas - PUCRS

🇧🇷

Porto Alegre, RS, Brazil

Hospital de Cancer de Barretos

🇧🇷

Barretos, SP, Brazil

Hospital Amaral Carvalho

🇧🇷

JAU, SP, Brazil

Hospital Sírio-Libanês

🇧🇷

Sao Paulo, SP, Brazil

Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

🇧🇷

Sao Paulo, SP, Brazil

Hospital A. C. Camargo; Oncologia

🇧🇷

Sao Paulo, SP, Brazil

Royal Victoria Regional Health Centre

🇨🇦

Barrie, Ontario, Canada

Lakeridge Health Oshawa

🇨🇦

Oshawa, Ontario, Canada

Thunder Bay Regional Health Sciences Centre; Clinical Trials Department

🇨🇦

Thunder Bay, Ontario, Canada

North York General Hospital

🇨🇦

Toronto, Ontario, Canada

Princess Margaret Cancer Center

🇨🇦

Toronto, Ontario, Canada

CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital

🇨🇦

Chicoutimi, Quebec, Canada

CISSS Chaudière-Appalaches

🇨🇦

Levis, Quebec, Canada

Centre Hospitalier de l'Universite de Montreal (CHUM)

🇨🇦

Montreal, Quebec, Canada

McGill University Health Centre - Glen Site

🇨🇦

Montreal, Quebec, Canada

CHU de Québec - Hôpital du Saint-Sacrement

🇨🇦

Quebec City, Quebec, Canada

Hopital regional de saint jerome

🇨🇦

Saint-jerome, Quebec, Canada

Centre hospitalier regional de Trois-Rivieres

🇨🇦

Trois-Rivieres, Quebec, Canada

Saskatoon Cancer Centre

🇨🇦

Saskatoon, Saskatchewan, Canada

Oncovida

🇨🇱

Providencia, Chile

The Affiliated Hospital of Xuzhou Medical University

🇨🇳

Xuzhou, China

Zhejiang Cancer Hospital

🇨🇳

Zhejiang, China

The First Affiliated Hospital of Zhengzhou University

🇨🇳

Zhengzhou, China

Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo

🇨🇴

Bogota, D.C., Colombia

IPS Salud SURA Chipichape Cali

🇨🇴

Cali, Colombia

Oncomedica S.A.

🇨🇴

Monteria, Colombia

Sociedad de Oncología y hematología del Cesar Ltda

🇨🇴

Valledupar, Colombia

Clinica CIMCA

🇨🇷

San José, Costa Rica

ICIMED Instituto de Investigación en Ciencias Médicas

🇨🇷

San José, Costa Rica

Proclinical Pharma

🇨🇷

San José, Costa Rica

Kuopio Uni Hospital; Oncology Dept

🇫🇮

Kuopio, Finland

Tampere University Hospital

🇫🇮

Tampere, Finland

Institut Sainte Catherine

🇫🇷

Avignon, France

HOPITAL JEAN MINJOZ; Oncologie

🇫🇷

Besancon, France

Centre Francois Baclesse; Comite Sein

🇫🇷

Caen, France

Centre Jean Perrin

🇫🇷

Clermont Ferrand, France

Centre Hospitalier Saint Louis; Oncologie Medicale

🇫🇷

La Rochelle, France

Centre Oscar Lambret; Cancerologie Gynecologique

🇫🇷

Lille, France

IUCT Oncopole

🇫🇷

Toulouse, France

Gustave Roussy

🇫🇷

Villejuif, France

DONAU ISAR Klinikum Deggendorf; Frauenklinik

🇩🇪

Deggendorf, Germany

RCCS - Centro di Riferimento; Oncologia Medica B

🇮🇹

Aviano (PN), Friuli-Venezia Giulia, Italy

A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia

🇮🇹

Udine, Friuli-Venezia Giulia, Italy

Policlinico Universitario Agostino Gemelli

🇮🇹

Roma, Lazio, Italy

Università Campus Bio-Medico di Roma; Oncologia Medica

🇮🇹

Roma, Lazio, Italy

ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica

🇮🇹

Brescia, Lombardia, Italy

Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1

🇮🇹

Milano, Lombardia, Italy

Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia

🇮🇹

Rozzano, Lombardia, Italy

Ospedale Di Macerata; Oncologia

🇮🇹

Macerata, Marche, Italy

A.O.U. Maggiore della Carità

🇮🇹

Novara, Piemonte, Italy

Presidio Ospedaliero di Summa-Perrino; Oncologia Medica

🇮🇹

Brindisi, Puglia, Italy

Humanitas Centro Catanese Di Oncologia; Oncologia Medica

🇮🇹

Misterbianco (CT), Sicilia, Italy

Azienda Ospedaliera Universitaria Careggi

🇮🇹

Florence, Toscana, Italy

IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II

🇮🇹

Padova, Veneto, Italy

Kyungpook National University Chilgok Hospital

🇰🇷

Daegu, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

Seongnam-si, Korea, Republic of

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System; Clinical Pharmacy

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Ewha Womans University Mokdong Hospital

🇰🇷

Seoul, Korea, Republic of

Ulsan University Hosiptal

🇰🇷

Ulsan, Korea, Republic of

Panamerican Clinical Research S.A de C.V.

🇲🇽

Guadalajara, Jalisco, Mexico

Productos y Servicios Oncologicos Acacias SA de CV

🇲🇽

Ciudad de México, Mexico CITY (federal District), Mexico

Centro Oncológico Hematológico Roma

🇲🇽

Mexico City, Mexico CITY (federal District), Mexico

Centro de Investigacion Clinica de Oaxaca

🇲🇽

Oaxaca de Juárez, Oaxaca, Mexico

PanAmerican Clinical Research, Querétaro

🇲🇽

Santiago de Querétaro, Queretaro, Mexico

CENEIT Oncologicos; DENTRO DE CONDOMINIO SAN FRANCISCO

🇲🇽

Mexico City, Mexico

Centro Medico Dalinde

🇲🇽

Mexico City, Mexico

Palmerston North Hospital; Regional Cancer Treatment Service

🇳🇿

Palmerston North, New Zealand

Whangarei Hospital; Aotearoa Clinical Trials Clinic Room

🇳🇿

Whangarei, New Zealand

Centro Medico Monte Carmelo

🇵🇪

Arequipa, Peru

Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional

🇵🇪

Lima, Peru

Instituto Nacional de Enfermedades Neoplasicas

🇵🇪

Lima, Peru

Clínica Santa Beatriz

🇵🇪

Lima, Peru

Instituto Peruano de Oncología y Radioterapia

🇵🇪

Lima, Peru

Oncosalud Sac; Oncología

🇵🇪

Lima, Peru

?wi?tokrzyskie Centrum Onkologii; Dzia? Chemioterapii

🇵🇱

Kielce, Poland

Przychodnia Lekarska KOMED, Roman Karaszewski

🇵🇱

Konin, Poland

Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii

🇵🇱

Koszalin, Poland

Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli; Oddzial Onkologii Klinicznej

🇵🇱

Lublin, Poland

Mazowiecki Szpital Wojewódzki im. ?w. Jana Paw?a II; Oddzial Onkologii Klinicznej i Radioterapii

🇵🇱

Siedlce, Poland

Zachodniopomorskie Centrum Onkologii; O?rodek Bada? Klinicznych

🇵🇱

Szczecin, Poland

Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr

🇵🇱

Warszawa, Poland

IPO de Coimbra; Servico de Oncologia Medica

🇵🇹

Coimbra, Portugal

Hospital de S. Francisco Xavier; Unidade de Oncologia Medica

🇵🇹

Lisboa, Portugal

Hospital da Luz; Departamento de Oncologia Medica

🇵🇹

Lisboa, Portugal

IPO do Porto; Servico de Oncologia Medica

🇵🇹

Porto, Portugal

CHVNG/E_Unidade 1; Servico de Oncologia Medica

🇵🇹

Vila Nova de Gaia, Portugal

National University Hospital; National University Cancer Institute, Singapore (NCIS)

🇸🇬

Singapore, Singapore

National Cancer Centre; Medical Oncology

🇸🇬

Singapore, Singapore

Icon Cancer Centre Gleneagles

🇸🇬

Singapore, Singapore

Institute of Oncology Ljubljana

🇸🇮

Ljubljana, Slovenia

Cancercare Rondebosch Oncology

🇿🇦

Cape Town, South Africa

Cancercare

🇿🇦

Port Elizabeth, South Africa

Institut Catala d?Oncologia Hospital Germans Trias i Pujol

🇪🇸

Badalona, Barcelona, Spain

Hospital Univ Vall d'Hebron; Servicio de Oncologia

🇪🇸

Sant Andreu de La Barca, Barcelona, Spain

Hospital de Jerez de la Frontera; Servicio de Oncologia

🇪🇸

Jerez de La Frontera, Cadiz, Spain

Hospital Quiron de Madrid; Servicio de Oncologia

🇪🇸

Pozuelo de Alarcon, Madrid, Spain

© Copyright 2024. All Rights Reserved by MedPath